Acute treatment of migraine with dihydroergotamine nasal spray

Archives of Neurology

Volumn 53, Issue 12, 1996, Pages 1285-1291

  Gallagher, R Michael ^a  

^a University Headache Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROERGOTAMINE MESILATE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INTRANASAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MIGRAINE; NEUROLOGIC DISEASE; NOSE CONGESTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS;

EID: 0030479886     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.1996.00550120097022     Document Type: Article

References (39)

1. Horten BT. A new product in the treatment of migraine: a preliminary report. Proc Staff Meet Mayo Clin. 1945;20:241-249.
2. Goldstein J. Ergot pharmacology and alternative delivery systems for ergotamine derivatives. Neurology. 1992;42:45-46.
3. Schran HF, Tse FLS, Chang C-T, et al. Bioequivalence and safety of subcutaneously and intramuscularly administered dihydroergotamine in healthy volunteers. Curr Ther Res. 1994;55:1501-1508.
4. Callaham M, Raskin N. A controlled study of dihydroergotamine in the treatment of acute migraine headache. Headache. 1986;26:168-171.
5. Robbins L, Remmes A. Outpatient repetitive intravenous dihydroergotamine. Headache. 1992;32:455-458.
6. Raskin NH. Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology. 1986;36:995-997.
7. Silberstein SD, Schulman EA, Hopkins MM. Repetitive intravenous DHE in the treatment of refractory headache. Headache. 1990;30:334-339.
8. Winner P, Dalessic D, Mathew N, et al. Office-based treatment of acute migraine with dihydroergotamine mesylate. Headache. 1993;33:471-475.
9. Saadah HA. Abortive headache therapy with intramuscular dihydroergotamine. Headache. 1992;32:18-20.
10. Klapper JA, Stanton J. Clinical experience with patient administered subcutaneous dihydroergotamine mesylate in refractory headaches. Headache. 1992; 32:21-23.
11. Ward TN, Scott G. Dihydroergotamine suppositories in a headache clinic. Headache. 1991;31:465-466.
12. Massiou H. Dihydroergotamine nasal spray in prevention and treatment of migraine attacks: two controlled trials versus placebo. Cephalalgia. 1987;7 (suppl):440-441.
13. Krause KH, Bleicher MA. Dihydroergolamine nasal spray in the treatment of migraine attacks. Cephalalgia. 1985;5(suppl):138-139.
14. Roht J, Dufrense JJ. Dihydroergotamine nasal spray for the treatment of migraine attacks: a comparative double-blind crossover study with placebo. Cephalalgia. 1985;5(suppl):142-143.
15. Bousser MG, Loria Y. Efficacy of dihydroergotamine nasal spray in the acute treatment of migraine attacks. Cephalalgia. 1985;5(suppl):554-555.
16. Pavia T, Esperance P, Marcelino L, Assis G, Grupo de Estudios de Cefaleias. A double-blind trial with dihydroergotamine spray in migraine crisis. Cephalalgia. 1985;5(suppl):140-141.
17. Tulunay FC, Karan O, Aydin N, Culcuoglu A, Guvener A. Dihydroergotamine nasal spray during migraine attacks: a double-blind crossover study with placebo. Cephalalgia. 1987;7:131-133.
18. Ziegler D, Ford R, Kriegler J, et al. Dihydroergotamine nasal spray for the acute treatment of migraine. Neurology. 1994;44:447-453.
19. The Dihydroergotamine Nasal Spray Multicenter Investigators. Efficacy, safety, and tolerability of dihydroergotamine nasal spray as monotherapy in the treatment of acute migraine. Headache. 1995;35:177-184.
20. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias, and facial pain. Cephalalgia. 1988;8(suppl):19-28.
21. Elkind AH. Matching dosage forms to the needs of your headache patient. Headache Q Curr Treatment Rss. 1992;3(suppl):16-21.
22. Lipton RB, Stewart WF, Celentano DD, Reed ML. Undiagnosed migraine headaches: a comparison of symptom-based and reported physician diagnosis. Arch Intern Med. 1992;152:1273-1278.
23. Silberstein SD. Migraine symptoms: results of a survey of self-reported migraineurs. Headache. 1995;35:387-396.
24. Volans GN. Migraine and drug absorption. Clin Pharmacokinet. 1978;3:313-318.
25. Carstairs LS. Headache and gastric emptying time. Proc R Soc Med. 1958; 51:790-791.
26. Kreel L. The use of metoclopramide in radiology. Postgrad Med J. 1973;49 (suppl):42-45.
27. Boyle R, Behan PO, Sutton JA. A correlation between severity of migraine and delayed gastric emptying measured by an epigastric impedance method. Br J Clin Pharmacol. 1990;30:405-409.
28. Raskin NH. Migraine: treatment. In: Headache. 2nd ed. New York, NY: Churchill Livingstone Inc; 1988:135-213.
29. Tfelt-Hansen P, Olesen J, Aebelholt-Krabbe A, Melgaard B, Veillis B. A double-blind study of metoclopramide in the treatment of migraine attacks. J Neurol Neurosurg Psychiatry. 1980;43:369-371.
30. Schran HF, Tse FL. Pharmacokinetics of dihydroergotamine following subcutaneous administration in humans. Int J Clin Pharmacol Ther Toxicol. 1985; 23:1-4.
31. Hilke H, Kanto J, Kleimola T, Mantyla R Intramuscular absorption ot dihydroergotamine in man. Int J Clin Pharmacol Biopharm. 1978;16:277-278.
32. Kanto J. Clinical pharmacokinetics of ergotamine, dihydroergotamine, ergotoxine, bromocriptine, methysergide, and lergotrile. Int J Clin Pharmacol Ther Toxicol. 1983;21:135-142.
33. Rarton CW. Evaluation and treatment of headache patients in the emergency department: a survey. Headache. 1994;34:91-94.
34. Klapper JA, Stanton J. Current emergency treatment of severe migraine headaches. Headache. 1993;33:560-562.
35. Silberstein SD. Evaluation and emergency treatment of headache. Headache. 1992;32:396-407.
36. Jenzer G, Bremgartner MF. Dihydroergotamine as a nasal spray in the treatment of the migraine attack - efficacy and tolerability. Schweiz Rundsch Med Prax. 1990;79:914-917.
37. Cady RK, Wendt JK, Kirchner JR, Sargent JD, Rothrock JF, Skaggs H Jr. Treatment of acute migraine with subcutaneous sumatriptan. JAMA. 1991;265: 2831-2835.
38. Peroutka SJ. 5-Hydroxytryptamine receptor subtypes and the pharmacology of migraine. Neurology. 1993;43(suppl):S34-S38.
39. Lipton RB, Stewart WF. Migraine in the United States: a review of epidemiology and health care use. Neurology. 1993;43(suppl):S6-S10.